Paul Everson

BCMA(CD269) decoy receptor shows potential to treat Multiple Myeloma and Large B cell Lymphoma

Using a yeast display system, his group developed a BCMA mutant with higher affinity to TNF ligands APRIL and BAFF. This soluble decoy receptor showed anti-tumor effects in vitro and in vivo using mouse MM1.R and INA-6 tumor models. “Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma” Yu Rebecca

BCMA(CD269) decoy receptor shows potential to treat Multiple Myeloma and Large B cell Lymphoma Read More »

EV isolation to assess cognitive impairment in Parkinsons disease

Plasma derived neuronal enriched extracellular vesicles(EVs) were evaluated for content of α-synuclein and phosphorylated tau181. Ratio of α-synuclein to phosphorylated tau181 in these samples was signicantly higher for cognitively impaired Parkinson’s patients compared to cognitively normal Parkinson’s patients. Analysis of plasma EVs may be useful for prognosis of Parkinson’s disease. “Extracellular vesicle biomarkers for cognitive

EV isolation to assess cognitive impairment in Parkinsons disease Read More »

CD40 Bispecific Antibody increase T cell anti-tumor activity

“Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies” doi: 10.1136/jitc-2022-005018. PMID: 36323431 Karin Hägerbrand , Peter Ellmark, et al. J Immunother Cancer 2022 Nov;10(11):e005018 Tetrameric Bispecific antibodies specific to CD40 and either CD326(EpCAM) or CD66e(CEA) were tested on human cells in vitro

CD40 Bispecific Antibody increase T cell anti-tumor activity Read More »

Ancell anti-CD64(FcRI) F(ab’)2 used to block Phagocytosis of opsonized platelets

This study looked at the effect of glycosylation of anti-platelet antibody on ability of Macrophage mediated phagocytotic clearance in transfusion patients. F(ab’)2 of anti-CD64 mAb was used as a phagocytosis blocking control in vitro. “Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages“ Thijs L, Gesture Vidarsson, et al. Platelets  (2022) https://doi.org/10.1080/09537104.2022.2129604 

Ancell anti-CD64(FcRI) F(ab’)2 used to block Phagocytosis of opsonized platelets Read More »

CD166 Mesenchymal marker characterizes ADMPC for Periodontal transplant.

Ancell CD166/FITC used as a Mesenchymal marker to characterize Adipose Tissue-Derived Multilineage Progenitor cells (ADMPC) used for Periodontal transplant. The results of this study suggest tha autologous ADMPC transplantation may be a good option for treatment of severe periodontitis. “Periodontal Regeneration by Allogeneic Transplantation of Adipose Tissue Derived Multi-Lineage Progenitor Stem Cells in vivo.“ M

CD166 Mesenchymal marker characterizes ADMPC for Periodontal transplant. Read More »

Glioma treatment using Checkpoint inhibition + CAR looks promising!

CD133 specific CAR-macrophages created in situ using NanoPorter hydrogel in combination with CD47 checkpoint blocking antibody improves post operative Glioblastoma survival in a humanized mouse model “Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy” Chen Chen, Xinyi Jiang, et al. Science Translational Medicine 14: 656 DOI: 10.1126/scitranslmed.abn1128 CD47

Glioma treatment using Checkpoint inhibition + CAR looks promising! Read More »

Emerging importance of Siglecs in assisting tumor evasion of immune surveillance

Siglecs and their ligands are expressed by many tumors, and can serve to down-regulate immune response. REVIEW article: “The intriguing roles of Siglec family members in the tumor microenvironment” Kui-Ying Jiang, Ling Wang, et al. (2022) Biomarker Research 10: 22 PMID: 35418152 “Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10” Shan-Shan Yin, Feng-Hou Gao

Emerging importance of Siglecs in assisting tumor evasion of immune surveillance Read More »

Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”?

CF33-hNIS, a modified vaccinia (small pox) virus will be tested by IV or Intratumoral injection, with or without PD-1 inhibitor, pembrolizumab in patients with advanced or metastaic solid tumors. Link to Medical News Today Article Link to Clinical Trial Link to a Background article Ancell human PD-1 related Research Products CD279(PD-1) CD274 (PD-L1) CD273 (PD-L2)

Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”? Read More »

ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety

“Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies” Natasha Helleberg Madsen, Monika Gad, Jesper Larsen. (Feb 5, 2022) J Immunol Methods 502: 113231. https://doi.org/10.10 PBMC were stimulated with immobilized ANC28.1, CD28.1 and muromonab CD3. Assessed Cytokines and levels of Activation molecules by flow could determine the

ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety Read More »